Review on the induction of obesity in laboratory animals by Aswar, Urmila et al.
ORIGINAL ARTICLE
Diabesity 2019, Volume 5, Number 1: 11-18
www.diabesity.ejournals.ca Diabesity 2019; 5(1): 11-18. doi: 10.15562/diabesity.2019.58 11
CrossMark
ABSTRACT
Valid animal models are essential for successful screening of novel 
therapeutic strategies against all types of diseases. Development 
or selection of an animal model that resembles the human disease 
process and symptoms is dependent on a robust knowledge of the 
natural history and pathogenesis of the disease. The use of animal 
models thus becomes to understand the underlying physiological and 
genetic basis of energy regulation, taste and smell perception and 
food choice behaviour. Obesity is a chronic metabolic disorder which 
results from multiple etiologies like genetic, physiological, epigenetic 
and environmental factors. Animal models of obesity include direct 
measurement of food intake to long-term studies in animals exhibiting 
continuous overconsumption of food containing high calories and 
fat. It is of prime importance that we must choose the right models 
with high face, construct and predictive validity. Failing to select 
and use appropriate animal models impede successful discovery and 
development of safer and more potent therapeutics and prevent 
wastage of money and time. We have thus provided a short review 
on currently available animal models of obesity. We discuss different 
method of induction of obesity in laboratory animals as well as the 
transgenic animals used in anti obesity drug discovery.
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INTRODUCTION
Obesity, defined as a body mass index (BMI) 
>30kg/m2, is a signiﬁcant health problem. In 
human BMI between 30 and 34.9, between 35 and 
39.0, more than 40 is called as class I, class II and 
morbidity obesity respectively. Type -1 obesity 
caused by excessive eating habits, sedentary lifestyle 
and lack of physical activities is most common. 
Type-2 obesity caused by disease such as Cushing’s 
syndrome, hypothyroidism, polycystic ovarian 
disease and insulinoma is observed in less than 1% 
population. Enlargement of fat cells in the body 
results in child and adult type of obesity. Abdominal 
and limb obesities mainly occur in men and women 
respectively. Obesity results from an imbalance of 
food intake, basal metabolism, and energy expen-
diture. Changes in the lifestyle, financial status, 
society, lack of physical activity, improvisation in 
transport mechanisms, increased as well as altered 
work shifts and the worldwide availability of nutri-
tion have driven the obesity epidemic over recent 
decades. Modernization, urbanization and global-
ization of food markets are the important elements 
that have significantly contributed to the obesity. At 
an individual level, multiple endogenous or envi-
ronmental causes could lead to obesity. However, 
in most cases, a combination of excessive caloric 
intake and availability of energy-dense meals is 
thought to be the main contributor to obesity. 
There are different methods used in the clinic 
to assess obesity, anthropomorphic measurement 
includes total body fat composition, waist circum-
ference and skinfold thickness measurements. 
Other more advanced methods are hydrostatic 
weighing, air displacement plethysmography, 
bioimpedance analysis, dual- energy X-ray absorp-
tiometry (DXA) and quantitative magnetic reso-
nance (qMR) measurement, ultrasonography is 
also used to measure the thickness of subcuta-
neous fat, muscle and intra-abdominal depth.1 A 
precise assessment of body fat distribution can be 
obtained from Computerized Tomography (CT) 
and Magnetic Resonance Imaging (MRI) also.
Obesity is associated with substantial increases 
in morbidity, premature mortality, impaired 
quality of life and large healthcare costs.2,3 More 
severe cases of it are associated with an endothelial 
dysfunction, increased incidence of sleep apnoea, 
asthma, gallstones, steatohepatitis, glomeruloscle-
rosis and dyslipidaemia. The major comorbidities 
include type 2 diabetes, metabolic syndrome, 
hypertension, dyslipidaemia, myocardial infarc-
tion, stroke, certain cancers, sleep apnoea and 
osteoarthritis.4,5
Life style management, dieting does not produce 
a marked reduction. Bariatric surgery, gastric band-
ing is effective however perioperative morbidity 
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Answers to the comments raised for our article entitled ‘Short review on the induction of obesity in 
laboratory animals’ is given below. Kindly consider.
Sr.no
 Reviewer A
(Comments) Explanation
1 Introduction 1st paragraph - The mention of 6 different 
types of obesity is not clear. Basically, I have not heard 
of such a classification system for obesity. The original 
reference link to this topic seems to be no longer 
working and no other proof for such a classification 
exists. Therefore, either the authors find a valid reference 
to these statements or delete these lines
Mentioned Lines were deleted.
2 Introduction 5th paragraph – The 1st sentence is not 
clear 
“………. As well as continuation of substance abuse”. 
I would delete the last part of the sentence as it 
complicates the sentence.
The last part of sentence is deleted
3 Adding few lines on the advantages and disadvantages of 
each animal model would enrich the review significantly
Advantages and disadvantages is now added
4 Overall, I think more discussion needs to be added into 
each model. Some are just few sentences which is very 
short given the published informationout there
Discussion has been added along with 
conclusion.
5 Table 1 – Composition of high fat diet section is written 
inconsistently. Either use kcal/g or % or both throughout 
the table
Correction has been done. Now the values 
are mentioned in % for the diet which is 
available. In case of HFSS and Cafeteria diet, 
we could not find the reference that provides 
in percentage. Considering, these references as 
very recent, we have kept it as such.
6 Table1 – as per the author guideline, table should be 
double spaced
Correction has been done.
7 Add references to the Cafeteria diet-induced obesity 
section. Similarly,add references to any sentences other 
than that of the authors ownstatements throughout the 
manuscript
References are now added as suggested. 
8 Title page – please refer to author guidelines to add 
missing info
Required correction is now done.
9 Reference section – Needs reformatting according to the 
journal style
References are now as per the journal style.
10 The manuscript requires thorough screening and 
correction for formatting, grammar and language errors.
Grammar and language correction now has 
been done.
Sr.no
REVIEWER B
(Comments) Explanation 
1 Information on which models have been used previously 
for anti-obesity drug studies was provided 
Relevant information has been given.
2 advantages/disadvantages of each model for use in anti-
obesity drug studies
Advantages and disadvantages are now added 
for each animal model.
3 lack of referencing for statements and points made 
throughout the paper. The authors will need to include 
more references tofully support the information.
References are now added.
4 Developparagraphs of 5 to 6 sentences to discuss topics.  The changes are now considered.
5 A few sentences that were verbatim or very closely 
worded to sentences in the first reference,
The sentences have been removed.
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and surgical complications are the associated 
drawbacks.6,7 
Consumption of palatable foods, rich in fat 
and sugar is shown to activate the mesolimbic 
dopamine pathway which plays an important role 
in the development of excessive caloric intake. 
Psychostimulants that augments brain dopamine 
level has shown to induce anorexia therefore are 
used as supplements marketed to curb obesity. 
Amphetamine derivatives desoxyephedrine, phen-
termine and diethylpropion, rimonabant, sibutra-
mine, fenfluramine and dexfenfluramine were 
among the earliest pharmacological agents used 
for weight loss and withdrawn from the market 
due to abuse liabilities and severe side effects. The 
current drug approved by FDA is orlistat which is a 
lipase inhibitor.8 Lorcaserin, metformin, exenatide, 
liraglutide, semaglutide, amylin, pramlinatide and 
bupropion and naltrexone are some other antiobe-
sity drugs.9,10 Current drug discovery demonstrates, 
conventional monotherapies which are getting 
replaced with polytherapy.11 Also, surge of weight 
reducing products from herbs and alternative and 
complementary medicine in markets as well as 
increased work out centres are evident.12,13 Hence, 
it can be understood that the drug discovery in 
antiobesity sector is highly growing and lucrative. 
Animal models remain indispensable for discovery, 
validating and optimizing novel therapeutics for 
their safe use in humans. The laboratory animals 
share similar characteristics of human obesity and 
its co-morbidities be developed in the quest for 
novel preventions and/or treatments. The objective 
of this review is to describe different method of 
induction of obesity in laboratory animals as well 
as the use of transgenic animals in anti-obesity drug 
discovery.
SEX DIFFERENCE AND OBESITY
In human’s differences exist between the two sexes 
in terms of energy expenditure and requirements 
as well as in fat metabolism and fat distribution.14 
Greater storage of fat in the lower body parts in 
females is because of lower basal fat oxidation 
and increased number of ɑ2-adrenoceptors, while 
decreased ɑ2-adrenergic sensitivity in the abdom-
inal region. This may lead to more likely storage of 
fat in thigh region than the abdomen compared with 
men who have greater storage of fat in the upper 
body part. Moreover, women have more subcuta-
neous fat than men. In laboratory rats, males gain 
weight steadily throughout their lives while the 
body weight of female rats becomes stable in early 
adulthood.15 Sex difference also persists in most 
rodent models of Type 2 Diabetes Mellitus (T2DM) 
and the Zucker rat (obese rat). As a result, female 
rats are better models for studying obesity during 
adulthood since they are more like humans in their 
growth patterns.16 In addition, subcutaneous fat 
is found more in females due to higher concen-
trations of estrogen and progesterone receptors 
in these depots whereas males have more visceral 
fat. Sex of the animals is also associated with the 
deviation in the cellular response of the adipose 
tissue to high-fat feeding diet. Previous studies have 
shown that when 10-day old Wistar rats were fed 
a cafeteria diet for 14 weeks, female rats exhibited 
more weight gain than their male counterparts. 
Studies on 12  h  fasted rats demonstrated that sex 
difference rats had greater food intake with corre-
sponding rise in ghrelin and decrease in leptin level. 
Administration of fat to NMRI mice for 14 weeks 
resulted in accumulation of fat in retroperitoneal 
and parametrial sites in females, and in subcuta-
neous depot in males signifying the relationship 
between fat cell hypertrophy and the level of lard 
in the diet specific to site and sex.17 On the contrary, 
male mice and rats are considered as gold stan-
dards for studying dietary obesity because of the 
absence of estrous cycle in male rats. Estrous cycle 
of the female animals is repeated every 4–6 d and 
is observed to affect the food intake of the animal 
during this period.18
The present review discusses the different 
animal models used to study obesity. The aim of the 
review is to provide the details of diet, chemicals 
and drugs as well as various surgical models used in 
laboratory to induce obesity and allied biochemical 
changes like hypercholesteremia and hyperglycae-
mia so as to study anti-obesity drugs. 
1. Diet-induced (hypercaloric diets) obesity 
 1.1 High fat diet
 1.2 High fat high carbohydrate diet
 1.3  High fat high salt high sucrose diet
 1.4 Cafeteria diet
2. Maternal overfeeding
3. Drug induced obesity
4. Chemical induced obesity
5. Surgical model
 5.1 Ovariectomy
 5.2 Castration
 5.3  Ventromedial hypothalamic nucleus 
(VMH) lesion
6 Age related obesity
7 Stress induced obesity
8 Genetic models 
1. Diet-induced (hypercaloric diets) obesity
High fat diet (HFD)
The physiological mechanisms considered to be 
involved in high-fat diet induced obesity are associ-
ated with overconsumption of high-fat diets due to 
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their low satiating effects, changes in the enzymes 
and hormones that are involved in energy balance, 
such as high-fat diet-induced hyperleptinemia and 
hyperinsulinemia accompanied by leptin and insu-
lin resistance, and reduced suppression of ghrelin 
release.19
Diet induced obesity model usually takes longer 
time to develop obesity (about 3- 5 months)20 (Refer 
table 1). There is existence of positive relation-
ship between the level of fat in the diet and body 
weight or gain of fat. C57BL/6 mice are genetically 
more susceptible to HFD induced obesity (central 
adiposity), impaired glucose tolerance, and T2DM. 
The specific fatty foods used in the diets vary across 
studies, ranging from Crisco fat, lard and palm oil, 
beef tallow, peanut butter etc,21 the human Western 
diet  also known as cafeteria diet (high-fat, high-
salt) is more useful in inducing obesity and other 
comorbidities than a conventional high-fat diet.22 
The method involves access of normal, lean rats or 
mice to diets high in fat over a period of 3-4 months. 
The most commonly evaluated parameters are 
weight gain, other physiological parameters involve 
altered blood pressure, biochemical parameters 
such as insulin resistance, glucose intolerance, 
elevated plasma leptin, elevated total cholesterol, 
LDL and triglycerides.23 HFD fed animals can be 
used to screen antiobesity, antihyperlipidemic and 
antidiabetic drugs. Advantages of HFD animal 
models is that it is inexpensive and it is based on 
type of diet involved. The model is appropriate for 
study of non-genetic lifestyle induced obesity. The 
disadvantage is the duration of diet regime which is 
around 16 weeks with delayed onset.24
1.4 Cafeteria diet-induced obesity
Cafeteria diets (CD) includes various palatable 
foods such as chocolate, peanuts, condensed milk, 
etc which mimics the western diet of humans. CD 
induced obesity mainly results from hyperphagia 
that may be attributed to increased energy expen-
diture due to diet-induced thermogenesis (DIT) 
resulting from sympathetic activation of brown fat. 
CD fed rats demonstrates rise in adiposity, hepa-
tosteatosis and inﬂammation in white fat, brown 
fat, and liver. Cafeteria diet differs from palatable 
diet in terms of meal frequency as well as meal size. 
(Table 1). The model helps in closely monitoring 
nutrients composition as well as insulin resistance 
and hypertriglyceridemia can be rapidly achieved. 
Table.no 1 Different diets with their compositions
Type of diet Composition of high fat diet Comment Reference
High fat diet 54% basic feed, 15% lard, 15% 
sucrose, 4% milk powder, 3% 
peanut, 5% egg yolk powder, 1% 
sesame oil, 2% salt, 0.6% dicalcium 
phosphate, and 0.4% mountain flour 
2 weeks of feeding with HFD 
made 2/3 of rats with significant 
increase in body weight gain.
8 weeks feeding with the diet 
showed marked rise in lipid 
profile
43
High fat high carb diet condensed milk (39.5%), beef 
tallow (20%), and fructose (17.5%). 
powdered rat food (15.5 %) together 
with 25% fructose in drinking water
16 weeks administration showed 
significant increase in body 
weight, energy intake, abdominal 
fat deposition, abdominal 
circumference. Biochemical 
parameters demonstrated T2DM, 
hyperinsulinemia, dyslipidaemia, 
and increased plasma leptin. 
Cardiovascular signs included 
increased systolic blood pressure, 
endothelial dysfunction, fibrosis, 
hypertrophy of heart.
44
High fat high salt high 
sucrose diet 
HFSS diet consisted of 8% NaCl 
(w/w) saturated fat (lard, 36.9% 
energy/kg), simple carbohydrates 
(sucrose, 27.3% energy/kg).
Increased visceral and 
subcutaneous adiposity after 
twelve weeks in female rats. 
45
Cafeteria diet The CAF diet (75 kcal/rat/day) 
comprised cookies (sweet or briny), 
milk chocolate, cereals, potato 
chips, processed meats, condensed 
milk with sugar, high-fat cheese 
(parmesan or provolone) provided 
in excess.
14 weeks of administration 
increased body weight and blood 
glucose level.
25
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It helps in understanding the linkage between body 
mass, quantity of consumed fat and effect from 
different type of fat.
2. Maternal overfeeding and exposure to 
high fat diets
Obesity in mother is considered as a high-risk factor 
responsible for developing obesity in offspring. 
Maternal obesity with increased food or nutri-
ent intake before and during gestation may cause 
obesity and glucose tolerance in adult offspring. 
Maternal overfeeding is demonstrated as a result in 
an ampliﬁed and prolonged leptin surge in neona-
tal rat offspring.25 The model helps for controlling 
the epidemic of obesity. The model can be used to 
study the genetic factors and the perinatal environ-
ment impacting specific developmental stages. The 
main disadvantage of this model is that focusing on 
maternal diet and maternal obesity for program-
ming of adult disease may have a negative impact 
on the obesity epidemic in successive generations.24
3. Drug induced obesity
Weight gain is a commonly observed as a side effect 
with many drugs especially antipsychotic and anti-
depressant medications. Decreased serotoninergic 
and dopaminergic activity and reduced sympathetic 
nervous system activity results in weight gain. The 
possible reason could be dopaminergic system works 
through reward hypothesis. Food and desire to eat 
food act as reward. The hypothalamus via releasing 
neuropeptides such as leptin, ghrelin, orexin, insulin 
and NPY regulates food intake. Most of the drugs 
interfere with these regulating peptides and brings 
obesity. Dry mouth due to anticholinergic effect 
increases intake of caloric beverages.26 Some of the 
examples are antipsychotic agents like clozapine, 
quetiapine; Antidepressants such as tricyclic anti-
depressants, antimanic e.g. lithium, anti-convulsant 
e.g. valproate, carbamazepine. Sex hormones, anti-
diabetic agents, antimigraine and antihistaminergic 
drugs, glucocorticoids, β-adrenergic receptor blocker 
are the other agents which fall in the drug induced 
obesity category. The model is useful to study the 
correlation with other metabolic syndromes but 
exhibit delayed onset which is a disadvantage.
4. Chemical induced model
Mono Sodium Glutamate (MSG) induced obesity
MSG (4.0 g/kg body weight, s.c.) on 1st to 5th day 
of birth to the mice pups make them obese from 
6th week onwards exhibiting vagal hyperactivity 
and sympatho-adrenal hypoactivity with resulting 
hyperinsulinemia and an increase of white fat. 
MSG can be administered (4-10 doses) subcutane-
ously or intraperitoneally, daily or alternatively to 
the neonatal rats to get obesity in their younger age. 
In animals MSG increases the regular food intake 
and causes metabolic disorder which increases the 
glucose, triglyceride, insulin and leptin levels.27
Gold thioglucose is used to induce obesity in 
rodents. Mice when administered with single intra-
peritoneal injection of gold thioglucose (0.8 mg/gm 
or 30 -40 mg/kg) demonstrates obesity in 15 days.27 
Gold thioglucose administration produces change 
in capillary permeability thereby in adequate 
blood supply to this area, hence leading to necro-
sis in ventromedial portion of hypothalamus. 
The glucose moiety present in gold thioglucose 
is considered important for producing the lesion. 
The lesion due to necrosis causes hyperphagia and 
consequent obesity. It also indicates the presence 
of special glucoreceptor cells in the ventromedial 
hypothalamus that are involved in the regulation of 
food intake. There is increase in body lipid, body 
lipogenesis and triglycerides. The main disadvan-
tage of this model is longer duration for induction 
of obesity and high mortality rate.
5. Surgical models
5.1 Ovariectomy in female rats
Preclinical studies in rat’s population suggest that 
abrupt hormone deprivation caused by ovariec-
tomy causes decline in estrogen level which leads 
to obesity and its metabolic sequelae. Ovariectomy 
produces attenuation of initial leptin levels followed 
by increase the same after seven weeks, called 
as leptin resistance. Ovariectomy studies in rats 
have demonstrated a relationship between bilat-
eral ovariectomy that leads to obesity with that of 
leptin resistance, insulin resistance, adiposity and 
total and LDL-cholesterol level.28 With the help of 
ovariectomy we can get better understanding of 
consequence of hormonal changes on obesity in 
women.29 The disadvantage is that every animal has 
to undergo surgery and onset of obesity may vary.
5.2 Castration in male rat
Androgen the primary steroid hormone produced 
by male gonad plays an important role in fat 
homeostasis. Androgen deprivation leads to obesity 
resulting in abdominal adiposity, excess visceral fat, 
increase of hepatic triglyceride levels, increase of 
fasting blood glucose levels. Low testosterone levels 
are also associated with obesity. Castrated rats 
accumulate fat predominantly in the abdominal 
subcutaneous area.30 Hypogonadism after castra-
tion has shown to produce abdominal obesity in 
high-fat diet (HFD)-in C57BL/6J mice.
5.3 Ventromedial hypothalamic nucleus 
(VMH) lesion
VMH is the main centre of brain for appetite 
control, satiety, adiposity and energy homeostasis. 
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It exhibits role in maintenance of reduced levels 
of triglycerides and cholesterol as well as inhibits 
development of Insulin Resistance. VMH lesion can 
be performed stereotaxically (Co-ordinates for rat 
brain: 1.6 mm posterior to the bregma, anteriorly; 
0.5 mm lateral to the midsagittal line, transversely; 
and 0.2 mm above the base of the skull, vertically) 
with 1 mA of current intensity and 10 s duration. 
Post lesion significant rise in serum cholesterol and 
body weight is observed.31
6. Age-related obesity
Age is another important parameter that has 
profound impact on outcomes in obesity. In 
humans, body weight increases with age and peaks 
at about 55 years in both men and women. Aging 
has been associated with insulin resistance due to 
increase accumulation of intramuscular and intra-
hepatic fat. Ageing has been proposed to be an inde-
pendent determinant of glucose tolerance, which 
progressively worsens with age. Progressive decline 
in androgens as well as other metabolic hormones 
also accelerate obesity in aging individuals. 
The body weight of the C57BL/6J mouse, the most 
commonly used mouse strain for metabolic studies, 
increases with age, peak of obesity is observed at 
9 months. The 22-month old C57BL/6J mice exhibit 
reduced lean mass and increased fat mass compared 
with young 3-month-old mice. Glucose tolerance 
get affected more in rats than in mice. Studies have 
demonstrated increased body weight, glucose, 
cholesterol and leptin in aging rats.32
7. Stress induced Obesity
In human and non-human primates repeated expo-
sure to social stressors, results in increase in body 
weight, adiposity, and the intake of high calorie 
meals. Stress results in alteration in negative feed-
back mechanism due to repeated stimulation of the 
HPA axis and lead to metabolic changes33 Many 
studies have shown that long-term stress increases 
food intake and promotes weight and fat gain in 
human subjects.34 In addition, obesity is found 
to be associated with depression. It is previously 
reported that high food intake that corresponds 
with increased body weight in olfactory bulbec-
tomy induced depressed rats.35
8. Genetic Models
The inbred C57BL/6J mouse strain is widely used 
as a model for Diabetes Induces Obesity (DIO) 
because it is prone to develop severe obesity, elevated 
adiposity, glucose intolerance and moderate insulin 
resistance. Because of different metabolic changes 
that are encountered during study as stated above, 
the researchers must carefully optimize their strain 
selection on the basis demand of protocol and 
desired research findings. For example, for studying 
diabetes association with obesity, C57BL/6N strain 
but not C57BL/6J model may be the ideal choice 
asC57BL/6J strain rarely develops hyperglycaemia 
and islet atrophy when fed HFD, while C57BL/6N 
with HFD develops hepatosteatosis, hyperglycae-
mia and hyperinsulinemia.
C57BL/6J are the inbred strain susceptible 
to diet-induced obesity, type 2 diabetes, and 
atherosclerosis.36
Mice homozygous for the obese spontaneous 
mutation, Lep ob (commonly referred to as ob or 
ob/ob), are deficient in circulating leptin levels. 
They exhibit obesity, hyperphagia, transient hyper-
glycaemia, glucose intolerance, and elevated plasma 
insulin. They are also hypometabolic, hypothermic 
and subfertile. 
The ob/ob mice suffer from pronounced diabe-
tes mellitus marked by severe hyperglycaemia and 
atrophy of pancreatic islets, leading to premature 
death.37 The ob/ob mouse model is mostly used 
to assess the potency of novel anti-obesity medi-
cations to overcome a strong hyperphagia-driven 
obese phenotype. 
The db/ db mice exhibit high plasma insulin 
demonstrated at 10-14 days, they are leptin defi-
cient and develops obesity at 4- 5 weeks. They 
exhibit polyphagia, proteinuria, glycosuria, poly-
uria, polydipsia, hyperinsulinemia despite of severe 
depletion of pancreatic β cells of islet. and are leptin 
receptor deficient.38 
The sand rat, a diurnal gerbil (Psammomys 
obesus), is an outbred polygenic model of nutri-
tion-dependent early-onset obesity with diabetic 
sequelae. In natural habitat, sand rat has access to 
low calorie, plant diet and is lean with normal blood 
glucose and body weight. In laboratory conditions 
and access to HFD, sand rat develops obesity and 
hyperglycaemia.39
The New Zealand Obese (NZO) mouse is another 
inbred polygenic strain that develops obesity at 4-5 
weeks, it also exhibitsT2DM due to dysregulated 
leptin signalling, insulin resistance and glycae-
mic disturbances. Adiposity in the NZO mouse is 
driven by a moderate hyperphagia, reduced energy 
expenditure and reduced voluntary activity.40 
The TALLYHO/Jng (TH) mouse is an inbred 
polygenic model of T2DM that exhibits moderate 
obesity. TH mice exhibit insulin resistance, abnormal 
pancreatic morphology and function. The pathogen-
esis of obesity and associated comorbidity resembles 
polygenic human.41 Advantage of above model is 
that it occurs spontaneously. Disadvantage is that it 
is expensive and mutation in leptin receptor cannot 
be correlated in human because it rarely occurs.24
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MACAQUES 
Rhesus macaque monkeys belong to group of 
large laboratory animals that develop late-onset 
obesity.42 Obesity develops over a period of about 
10–15 years, mainly due to overeating. Macaque 
obesity resembles with that of metabolic changes 
observed in human metabolic syndrome such as 
increased intra-abdominal fat, elevated basal insu-
lin, impaired glucose tolerance, and elevated serum 
triglycerides and cholesterol.
DISCUSSION
Obesity is characterised by high BMI (>30kg/m2). 
The use of animal models has been the keystone of 
our understanding of the underlying physiological 
as well as genetic basis of energy regulation and 
food choice behaviour. Animal obesities can be 
differentiated not only by their eitiology but also by 
behavioural characteristics. In view of the number 
of diversities in animal obesity only one type of 
animal model cannot serve as general model for 
human obesity. Thus, future animal research should 
include different animal models such as genetics, 
dietary, VMH and surgical methods which will help 
in qualitative and quantitative evaluation. This review 
has discussed the various approaches of developing 
various animal models for research and develop-
ment of novel anti-obesity drugs. The review aims at 
providing details of diet, chemicals and drugs as well 
as surgical models used in laboratory. The important 
factors that should be considered while designing the 
study are time as well as ease of developing the model, 
as it generally take two to three months for obesity to 
establish, type of diet fed to the animals as geograph-
ical diversity affects the food habit and type of food 
available in that area may differ. Hence, calculation of 
nutritive value of food may provide a better insight. 
The associated co morbidities such as type 2 diabetes, 
hypercholesteremia, atherosclerosis etc must also be 
considered. Biochemical evaluations of insulin, total 
cholesterol, HDL cholesterol, LDL cholesterol, and 
triglycerides level, fatty-acid synthase (FAS), weight 
of adipose tissue and expression of metabolic enzyme 
levels are the imperative markers that can be used to 
determine the metabolic changes in the body.
CONCLUSION
The review has summarized different animal 
models for obesity considering the conventional 
animal models, animal models where obesity is due 
to lifestyle, genetically modified models and higher 
animals. The selection of relevant animal model is 
very crucial depending upon.
(i) Availability of diet or feeding manipula-
tion and their role in development of obesity and 
relevant parameters, (ii) Selection of appropriate 
animal strain, quantification of biochemical param-
eters, (iii) Use of knockout rodent models so as to 
understand complexity with respect to neuronal 
circuits, food intake and energy balance. Other 
than animal models, surgical models can be used 
such as ovariectomy and castration which is more 
relevant to late onset diabetes.VMH lesion also, can 
be used to produce obesity as it is ultimate pathway 
for regulation of food in obesity.
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